Multiple sclerosis and other immunologic diseases

Seyfert, Sepp; Klapps, P.; Meisel, Christian; Fischer, Thea Kølsen; Junghan, U.M.

doi:10.1111/j.1600-0404.1990.tb00928.x

Cited by 72 publications

(60 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although this was similar to the frequency of 23–33% identified by many studies, [3]–[4], [9], [15]–[16], [22] elevated ANA has also been detected in higher (47–81%) [12], [18], [22] and lower (3%–19%) frequency in MS patients [5], [19]–[21], [23] in additional literature. It is important to note that ANA has been detected at a frequency of 32% at 1∶40 dilution, 13% at 1∶80, 5% at 1∶160 and in 3% at 1∶320 in healthy individuals.…”

Section: Discussionsupporting

confidence: 90%

Autoantibodies and Sjogren’s Syndrome in Multiple Sclerosis, a Reappraisal

et al. 2013

View full text Add to dashboard Cite

BackgroundRheumatologic diseases may cause neurologic disorders that mimic multiple sclerosis (MS). A panel of serum autoantibodies is often obtained as part of the evaluation of patients suspected of having MS.ObjectivesTo determine, in light of recently revised diagnostic criteria for MS, neuromyelitis optica, and Sjogren’s Syndrome, if testing for autoantibodies in patients with a confirmed diagnosis of MS would reveal a frequency or demonstrate a clinical utility divergent from previous reports or lead to identification of undiagnosed cases of Sjogren’s Syndrome.MethodsConvenience sample cross-sectional study of MS patients recruited from the OHSU Multiple Sclerosis Center.ResultsAutoantibodies were detected in 38% (35/91) of patients with MS and were not significantly associated with disease characteristics or severity. While four patients had SSA antibodies, none met diagnostic criteria for Sjogren’s Syndrome.ConclusionsRheumatologic autoantibodies are frequently found in MS patients and are not associated with disease severity or systemic rheumatologic disease. Our demonstration of the low specificity of these autoantibodies suggests that the diagnostic utility and cost-effectiveness of testing is not supported when there is strong clinical suspicion of MS and low clinical suspicion of rheumatologic disease.

show abstract

Section: Discussionsupporting

confidence: 90%

Autoantibodies and Sjogren’s Syndrome in Multiple Sclerosis, a Reappraisal

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Prior studies were inconsistent with respect to a possible increased risk of AIT in the MS population [2,4,29]. Among studies which were population-based, one did not find an increased risk, one with small sample sizes found an increased risk of Graves’ disease but not Hashimoto’s disease, while the Taiwanese study found a threefold increased risk of hypothyroidism in MS [4,5,6].…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have evaluated the occurrence of autoimmune thyroid disease (AIT) in the multiple sclerosis (MS) population, reporting prevalences ranging from 0.92 to 13.9% [1,2]. Some of these studies suggested that AIT is more common in individuals with MS as compared to the findings expected for the general population [3,4,5]; however, most of these studies did not use contemporaneous control groups.…”

Section: Introductionmentioning

confidence: 99%

The Incidence and Prevalence of Thyroid Disease Do Not Differ in the Multiple Sclerosis and General Populations: A Validation Study Using Administrative Data

Marrie¹,

Leung

et al. 2012

Neuroepidemiology

View full text Add to dashboard Cite

Background: Prior studies of a possible increased risk of autoimmune thyroid disease (AIT) in multiple sclerosis (MS) are inconsistent. We aimed to validate and apply administrative case definitions for the surveillance of AIT in MS. Methods: We used administrative health data to identify 4,192 persons with MS and an age-, sex- and geographically matched general population cohort (n = 20,940). We developed case definitions for AIT using International Classification of Disease-9/10 codes and prescription claims, compared them to medical records and applied them to estimate the incidence and prevalence of AIT. Results: When compared to medical records, the administrative case definition using ≥1 hospital or ≥2 physician or ≥2 prescription claims had a sensitivity of 73.5% and specificity of 98.4%. In 2005, the age-adjusted prevalence of AIT was 9.51% [95% confidence interval (CI) 8.46–10.6] in the MS population and 8.56% (95% CI 8.11–9.02) in the general population. The age-adjusted incidence of AIT per 100,000 persons per year was 422.8 (95% CI 204.4–641.3) in the MS population and 407.7 (95% CI 308.5–506.9) in the general population. From 1996 to 2005, the prevalence of AIT rose in both populations. Conclusion: Administrative data can be used for surveillance of AIT in MS. The incidence and prevalence of thyroid disease are similar in the MS and general populations.

show abstract

“…2 Bir organa spesifik olsun veya olmasın, MS hastalarında birtakım otoantikorların normal populasyona göre daha fazla bulunduğu görülmüştür. 3 Otoimmün tiroiditin ve tiroid fonksiyon bozukluklarının MS hastalarında kontrol grubuna göre yüksek bulunduğu daha önceki çalışmalarda gösterilmiştir. [4][5][6] Bu çalışmada MS hastalarında tiroid otoantikor düzeyleri ve otoimmün tiroiditin normal sağ-lıklı bireylerden farklı olup olmadığı ve interferon tedavisi sonrasında tedavi öncesi mevcut olmayan bir tiroid otoimmünitesinin ilaç etkisi ile gelişip gelişmediğinin belirlenmesi amaçlanmıştır.…”

unclassified